Plain-English answer
The Chinese section should not mirror every English page. It should explain the pages where translation reduces real decision risk. The highest-value Chinese pages are the ones that prevent expensive mistakes: confusing FDA authorization with hospital adoption, coding with payment, Medicare with Medicaid, coverage with reimbursement, U.S. commercial insurance with Chinese basic medical insurance, or physician interest with hospital purchasing approval. Those errors change budgets, timelines, evidence plans, and partner choices.
Selection logic
A full Chinese mirror would create duplicated maintenance work and could become inaccurate quickly. A selective layer is more useful because U.S. healthcare has many terms that are not intuitive to Chinese executives, investors, and product teams. The site should translate institutions only where translation improves judgment. That means prioritizing payment, regulation, coding, hospital purchasing, payer evidence, privacy, liability, and market-entry sequencing over broad general pages that Chinese readers can already understand from English or existing summaries.
The layer should also serve bilingual teams. A Chinese executive may need a short explanation of CPT or prior authorization before reading an English payer policy. A U.S. advisor may need to see which English terms are intentionally preserved in Chinese because replacing them would create false equivalence. The policy therefore treats translation as decision support, not localization decoration.
Priority topics
| Chinese-page priority | Reason | Source basis |
|---|---|---|
| FDA pathways | Chinese companies often treat clearance or approval as the main U.S. gate. | FDA Device Advice and product-center guidance. |
| Coding, coverage, reimbursement | The three terms are often collapsed into one idea of "payment." | CMS medical technology guidance, payer policies, Medicare coverage sources. |
| Medicare and Medicaid | They are distinct programs with different populations and federal/state roles. | CMS, Medicaid.gov, MedPAC, MACPAC. |
| Hospital purchasing | Clinical interest does not equal purchase authorization. | Value-analysis and provider procurement sources. |
| U.S. market entry | Market access depends on evidence, payment, support, liability, privacy, and trust. | FDA, CMS, payer, provider, and commercial diligence sources. |
Maintenance
Chinese access pages should be checked when U.S. payment rules, FDA guidance, CMS coding processes, Medicaid policy, privacy rules, or hospital purchasing dynamics change. They should also be checked when an English page changes the underlying concept. The Chinese page does not need to translate every sentence; it needs to preserve the decision logic. If the English page adds a new source distinction, the Chinese page should add the equivalent explanation in plain Chinese.
The selection threshold should stay high. A Chinese page is justified when it prevents a likely misunderstanding, supports a cross-border business decision, or explains a U.S. institution that has no clean Chinese equivalent. Pages should be retired, consolidated, or redirected if they become thin duplicates. The goal is a usable Chinese reader layer, not a second site that silently drifts away from the English reference library.
Research anchors
- CMS medical technology guide for U.S. coding, coverage, and payment language.
- FDA Device Advice for U.S. device pathway concepts.
- Medicaid.gov for Medicaid and CHIP program structure.
- MACPAC MACStats and MedPAC data books for program-specific evidence.